Infectious Disease Treatment Market

Industry Overview

The Global Infectious Disease Treatment Market is anticipated to grow from USD 85.5 Billion in 2023 to USD 130.1 Billion by 2030, thereby registering an 8.3% CAGR during the forecast period. Infection Disease Treatment is a genre of medicine that involves infection prevention and treatment. Infectious diseases are transmitted from person to person through indirect or direct contact. Patients must take anti-infective drugs in order to be treated for infectious diseases. Pathogens that cause infectious diseases include bacteria, viruses, fungi, and parasites. The host's defensive system is targeted directly in order to target the organism causing the ailment, and treatment is initiated. The large elderly population has emerged as a significant opportunity for the expansion of the infectious disease treatment industry. Thus, treatment for infectious diseases is crucial because it can shield people from serious sickness or even death.

Market Segmentation

Insight by Mode of Treatment

Based on the Mode of Treatment, The Global Infectious Disease Treatment Market is bifurcated into Drugs and Vaccines. The drug segment is further divided into Oral Administration, Topical, Injections, and Others. The drug segment is the dominant segment owing to the rising demand for sophisticated drugs, the rising geriatric population, increased availability of medicines over the counter, and rising disposable income. Furthermore, the increased frequency of hospital-acquired infections caused by inadequate cleaning or disinfection processes is likely to fuel demand for the drugs segment during the forecast period.

Vaccines are expected to be the fastest-growing category during the forecast period as it is increasingly adopted following the birth of a child until new diseases continue to emerge in the market along with their vaccinations.

Insight by Target Organism

The Global Infectious Disease Treatment Market is classified into Antibacterial, Antifungal, Antiviral, Antiparasitic, and Others based on Target Organism. The antibacterial drugs are further divided into Quinolones, Beta Lactams, Tetracyclines, Sulfonamides, and Others. The antifungal drugs are further divided into Azoles, Echinodians, Polyenes, Pyrimidines, and Others.  The antibacterial segment dominates the market and is anticipated to grow at a faster pace during the forecast period. The mounting prominence of diseases that are spread through bacteria and rising disposable income among people will lead to increased market demand to treat the infection. Hence, it is growing as a significant market potential for enhanced antibacterial drug sales and demand.

Insight by Disease Type

Based on Disease Type, the Global Infectious Disease Treatment Market is categorized into Bacterial, Viral, Parasitic, and Fungal. The viral diseases are further divided into AIDS, Hepatitis B, Hepatitis C, and Others. The bacterial diseases are further divided into Tuberculosis, Bacterial Meningitis, and Others. Bacterial disease type is expected to have a high CAGR during the forecast period owing to increase R&D programs initiated by key players for introducing novel drugs, the mounting number of people suffering from bacterial infection, weakened immunity system post COVID-19 crisis has led to considerable market opportunity for the global infectious disease treatment industry.

Insight on End User

Based on End User, the Global Infectious Disease Treatment Market is segregated into Online Pharmacies, Research Organisations, Retail Pharmacies, and Hospitals & Clinics. Hospitals & Clinics is anticipated to be the fastest growing category during the projected timeframe owing to the rising number of people visiting hospitals to treat infections, and the rising incidence of chronic infections that requires continuous checkups and treatments.

Global Infectious Disease Treatment Market Report Coverage

Industry Dynamics

Growth Drivers

Factors attributing to the market growth of the global infectious disease treatment industry include the rising prevalence of infectious diseases, rising geriatric population, increased market demand for novel drugs and therapies, favorable reimbursement policies by insurance companies, increased initiatives by the government to improve healthcare system, and increased responsiveness towards preventive measures, thereby accelerating market development of the industry. Moreover, in order to increase revenues, prominent market participants have released sophisticated medicines for treating infectious disorders. Also, the government has taken steps to provide sophisticated facilities to citizens in order to treat infectious diseases. Nevertheless, the increased R&D of advanced treatment products and the need to reduce the death toll linked with infectious diseases will propel market growth.

Challenges

The increased cost of treatment, lack of skilled professionals, and less per capita healthcare expenditure in emerging economies may stymie market expansion of the global infectious disease treatment industry. Additionally, the availability of alternate methods at a low cost and less knowledge of generic erosion may stymie the market expansion of the global infectious disease treatment industry.

Opportunities

The favourable implementation of technological development in healthcare centers and rising awareness of several diseases along with the benefits of early diagnosis among people will offer significant promising market opportunities for the global infectious disease treatment industry.

Geographic Overview

• North America
• Europe
• Asia Pacific (APAC)
• Rest of the World (RoW)

North America is expected to have the largest market share during the analysis timeframe due to favorable initiatives by the government, the rising occurrence of infectious diseases, rising awareness of the healthcare system, and increased funds & investment by the government.

Competitive Insight

The industry players are developing novel products to treat infectious diseases and are receiving approvals to commercialize products.

Roche focuses on the research and development of innovative medicines to address some of the world's most pressing health concerns, combining a deep background in infectious diseases with cutting-edge science and technology platforms. Roche infectious diseases research and development is currently focused on finding effective treatments for a variety of life-threatening infections such as viral hepatitis, influenza, multi-drug resistant bacteria, COVID-19, and HIV/AIDS. Roche has used a variety of strategies to combat the spread of these infectious diseases, including focusing efforts on developing treatments for the top three Gram-negative bacteria identified by the WHO as the top Priority Pathogens, continuing to innovate treatment solutions to prevent and treat influenza, and combining therapies that pair direct-acting antivirals with immune-enhancing molecules.

GSK plc. Is focused on treating infectious diseases by exploring and developing novel vaccines and specialty medicines against the major global health burden. Their combined knowledge of vaccinations and drugs allows them to concentrate on treatment and prevention. For example:

• Hepatitis B, using in-development antisense oligonucleotide and vaccine technologies
• Influenza, for which they are creating vaccinations and antibodies
• COVID-19, for which they are developing both treatments and vaccines

GSK plc. is concentrating its research efforts on respiratory viruses, antimicrobial research, shingles, meningitis, chronic hepatitis B (CHB), and neglected tropical diseases (NTDs).

Recent Development by Key Players

In June 2023, Pfizer Inc. announced that findings from late-stage trials showed that their experimental antibiotic combination was effective in treating severe illnesses caused by drug-resistant bacteria. Antibiotic-resistant bacteria, often known as superbugs, are killing people all around the world, and health officials have called for the discovery of innovative therapies as resistance to older antibiotics rises.

GSK and SCYNEXIS announce an exclusive agreement in March 2023 to commercialize and further develop Brexafemme (ibrexafungerp), a new, first-in-class medication for the treatment of fungal infections.

Key Players Covered in the Report

Some of the major players operating in the global infectious disease treatment industry include Merck & Co., Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, GSK plc, AstraZeneca, Novartis AG, Mylan N.V., Sanofi, Gilead Sciences, Inc., Bayer AG.

The Infectious Disease Treatment Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.

Segments Covered in the Report

• Mode of Treatment
  • Drugs
    • Oral Administration
    • Topical
    • Injections
    • Others
  • Vaccines
• Target Organism
  • Antibacterial
    • Quinolones
    • Beta Lactams
    • Tetracyclines
    • Sulfonamides
    • Others
  • Antifungal
    • Azoles
    • Echinodians
    • Polyenes
    • Pyrimidines
    • Others
  • Antiviral
  • Antiparasitic
  • Others
• Disease Type
  • Bacterial
    • Tuberculosis
    • Bacterial Meningitis
    • Others
  • Viral
    • AIDS
    • Hepatitis B
    • Hepatitis C
    • Others
  • Parasitic
  • Fungal
• End User
  • Online Pharmacies
  • Research Organisations
  • Retail Pharmacies
  • Hospitals & Clinics

Geographical Segmentation

• North America

• U.S.

• Canada

• Mexico

• Europe

• Germany

• U.K.

• France

• Italy

• Spain

• Russia

• Rest of Europe

• Asia-Pacific (APAC)

• China

• Japan

• India

• Rest of the World

• Brazil

• Saudi Arabia

• South Africa

•  U.A.E

• Other Countries

Source: VynZ Research

1.    Research Overview

        1.1.    The Report Offers
        1.2.    Market Coverage
                1.2.1.    By Mode of Treatment
                1.2.2.    By Target Organism
                1.2.3.    By Disease Type
                1.2.4.    By End User
                1.2.5.    By Region
        1.3.    Research Phases
        1.4.    Limitations
        1.5.    Market Methodology
                1.5.1.    Data Sources
                        1.5.1.1. Primary Research
                        1.5.1.2. Secondary Research
                1.5.2.    Methodology
                        1.5.2.1. Data Exploration
                        1.5.2.2. Forecast Parameters
                        1.5.2.3. Data Validation
                        1.5.2.4. Assumptions
                1.5.3.    Study Period & Data Reporting Unit

2.    Executive Summary

3.    Industry Overview

        3.1.    Industry Dynamics
                3.1.1.    Market Growth Drivers
                3.1.2.    Market Restraints
                3.1.3.    Key Market Trends
                3.1.4.    Major Opportunities
        3.2.    Industry Ecosystem
                3.2.1.    Porter’s Five Forces Analysis
                3.2.2.    Recent Development Analysis
                3.2.3.    Value Chain Analysis
        3.3.    Competitive Insight
                3.3.1.    Competitive Position of Industry Players
                3.3.2.    Market Attractive Analysis
                3.3.3.    Market Share Analysis

4.    Global Market Estimate and Forecast

        4.1.    Global Market Overview
        4.2.    Global Market Estimate and Forecast to 2030

5.    Market Segmentation Estimate and Forecast

        5.1.    By Mode of Treatment
                5.1.1.    Drugs
                        5.1.1.1. Market Definition
                        5.1.1.2. Market Estimation and Forecast to 2030 
                5.1.2.    Vaccines
                        5.1.2.1. Market Definition
                        5.1.2.2. Market Estimation and Forecast to 2030
                
        5.2.    By Target Organism
                5.2.1.    Antibacterial
                        5.2.1.1. Market Definition
                        5.2.1.2. Market Estimation and Forecast to 2030
                5.2.2.    Antifungal
                        5.2.2.1. Market Definition
                        5.2.2.2. Market Estimation and Forecast to 2030
                5.2.3.    Antiviral
                        5.2.3.1. Market Definition
                        5.2.3.2. Market Estimation and Forecast to 2030
                5.2.4.    Antiparasitic
                        5.2.4.1. Market Definition
                        5.2.4.2. Market Estimation and Forecast to 2030
                5.2.5.    Others
                        5.2.5.1. Market Definition
                        5.2.5.2. Market Estimation and Forecast to 2030
                
        5.3.    By Disease Type
                5.3.1.    Bacterial
                        5.3.1.1. Market Definition
                        5.3.1.2. Market Estimation and Forecast to 2030
                5.3.2.    Viral
                        5.3.2.1. Market Definition
                        5.3.2.2. Market Estimation and Forecast to 2030
                5.3.3.    Parasitic
                        5.3.3.1. Market Definition
                        5.3.3.2. Market Estimation and Forecast to 2030
                5.3.4.    Fungal
                        5.3.4.1. Market Definition
                        5.3.4.2. Market Estimation and Forecast to 2030

        5.4.    By End User
                5.4.1.    Online Pharmacies
                        5.4.1.1. Market Definition
                        5.4.1.2. Market Estimation and Forecast to 2030
                5.4.2.    Research Organisations
                        5.4.2.1. Market Definition
                        5.4.2.2. Market Estimation and Forecast to 2030
                5.4.3.    Retail Pharmacies
                        5.4.3.1. Market Definition
                        5.4.3.2. Market Estimation and Forecast to 2030
                5.4.4.    Hospitals & Clinics
                        5.4.4.1. Market Definition
                        5.4.4.2. Market Estimation and Forecast to 2030
                 
6.    North America Market Estimate and Forecast

        6.1.    By Mode of Treatment
        6.2.    By Target Organism
        6.3.    By Disease Type
        6.4.    By End User
        6.5.    By Country
                6.5.1.    U.S. Market Estimate and Forecast
                6.5.2.    Canada Market Estimate and Forecast
                6.5.3.    Mexico Market Estimate and Forecast

7.    Europe Market Estimate and Forecast

        7.1.    By Mode of Treatment
        7.2.    By Target Organism
        7.3.    By Disease Type
        7.4.    By End User
        7.5    By Country
                7.5.1.    Germany Market Estimate and Forecast
                7.5.2.    France Market Estimate and Forecast
                7.5.3.    U.K. Market Estimate and Forecast
                7.5.4.    Italy Market Estimate and Forecast
                7.5.5.    Spain Market Estimate and Forecast
                7.5.6.    Rest of Europe Market Estimate and Forecast

8.    Asia-Pacific Market Estimate and Forecast

        8.1.    By Mode of Treatment
        8.2.    By Target Organism
        8.3.    By Disease Type
        8.4.    By End User
        8.5.     By Country
                8.5.1.    China Market Estimate and Forecast
                8.5.2.    Japan Market Estimate and Forecast
                8.5.3.    India Market Estimate and Forecast
                8.5.4.    South Korea Market Estimate and Forecast
                8.5.5.    Singapore Market Estimate and Forecast
                8.5.6.    Rest of Asia-Pacific Market Estimate and Forecast

9.    Rest of the World (RoW) Market Estimate and Forecast

        9.1.    By Mode of Treatment
        9.2.    By Target Organism
        9.3.    By Disease Type
        9.4.     By End User
        9.5.     By Country
                9.5.1.    Brazil Market Estimate and Forecast
                9.5.2.    Saudi Arabia Market Estimate and Forecast
                9.5.3.    South Africa Market Estimate and Forecast
                9.5.4.    Other Countries Market Estimate and Forecast

10.    Company Profiles

        10.1.     Merck & Co., Inc.
                10.1.1.    Snapshot
                10.1.2.    Overview
                10.1.3.    Offerings
                10.1.4.    Financial Insight
                10.1.5.    Recent Developments
        10.2.     Pfizer Inc.
                10.2.1.    Snapshot
                10.2.2.    Overview
                10.2.3.    Offerings
                10.2.4.    Financial Insight
                10.2.5.    Recent Developments
        10.3.     F. Hoffmann-La Roche Ltd
                10.3.1.    Snapshot
                10.3.2.    Overview
                10.3.3.    Offerings
                10.3.4.    Financial Insight
                10.3.5.    Recent Developments
        10.4.    GSK plc
                10.4.1.    Snapshot
                10.4.2.    Overview
                10.4.3.    Offerings
                10.4.4.    Financial Insight
                10.4.5.    Recent Developments
        10.5.    AstraZeneca
                10.5.1.    Snapshot
                10.5.2.    Overview
                10.5.3.    Offerings
                10.5.4.    Financial Insight
                10.5.5.    Recent Developments
        10.6.    Novartis AG
                10.6.1.    Snapshot
                10.6.2.    Overview
                10.6.3.    Offerings
                10.6.4.    Financial Insight
                10.6.5.    Recent Developments
        10.7.     Mylan N.V.
                10.7.1.    Snapshot
                10.7.2.    Overview
                10.7.3.    Offerings
                10.7.4.    Financial Insight
                10.7.5.    Recent Developments
        10.8.     Sanofi
                10.8.1.    Snapshot
                10.8.2.    Overview
                10.8.3.    Offerings
                10.8.4.    Financial Insight
                10.8.5.    Recent Developments
        10.9.     Gilead Sciences, Inc.
                10.9.1.    Snapshot
                10.9.2.    Overview
                10.9.3.    Offerings
                10.9.4.    Financial Insight
                10.9.5.    Recent Developments
        10.10.   Bayer AG
                10.10.1. Snapshot
                10.10.2. Overview
                10.10.3. Offerings
                10.10.4. Financial Insight
                10.10.5. Recent Developments

11.    Appendix

        11.1.    Exchange Rates
        11.2.    Abbreviations

Note: Financial insight and recent developments of different companies are subject to the availability of information in the secondary domain.

List of Tables

Table 1 Sources
Table 2 Study Periods
Table 3 Data Reporting Unit
Table 4 Global Infectious Disease Treatment Market Size, By Mode of Treatment, 2018-2023 (USD Billion)
Table 5 Global Infectious Disease Treatment Market Size, By Mode of Treatment, 2025-2030 (USD Billion)
Table 6 Global Infectious Disease Treatment Market Size, By Target Organism, 2018-2023 (USD Billion)
Table 7 Global Infectious Disease Treatment Market Size, By Target Organism, 2025-2030 (USD Billion)
Table 8 Global Infectious Disease Treatment Market Size, By Disease Type, 2018-2023 (USD Billion)
Table 9 Global Infectious Disease Treatment Market Size, By Disease Type, 2025-2030 (USD Billion)
Table 10 Global Infectious Disease Treatment Market Size, By End User, 2018-2023 (USD Billion)
Table 11 Global Infectious Disease Treatment Market Size, By End User, 2025-2030 (USD Billion)
Table 12 Global Infectious Disease Treatment Market Size, by Region, 2018-2023 (USD Billion)
Table 13 Global Infectious Disease Treatment Market Size, by Region, 2025-2030 (USD Billion)
Table 14 North America Infectious Disease Treatment Market Size, By Mode of Treatment, 2018-2023 (USD Billion)
Table 15 North America Infectious Disease Treatment Market Size, By Mode of Treatment, 2025-2030 (USD Billion)
Table 16 North America Infectious Disease Treatment Market Size, By Target Organism, 2018-2023 (USD Billion)
Table 17 North America Infectious Disease Treatment Market Size, By Target Organism, 2025-2030 (USD Billion)
Table 18 North America Infectious Disease Treatment Market Size, By Disease Type, 2018-2023 (USD Billion)
Table 19 North America Infectious Disease Treatment Market Size, By Disease Type, 2025-2030 (USD Billion)
Table 20 North America Infectious Disease Treatment Market Size, By End User, 2018-2023 (USD Billion)
Table 21 North America Infectious Disease Treatment Market Size, By End User, 2025-2030 (USD Billion)
Table 22 North America Infectious Disease Treatment Market Size, by Region, 2018-2023 (USD Billion)
Table 23 North America Infectious Disease Treatment Market Size, by Region, 2025-2030 (USD Billion)
Table 24 Europe Infectious Disease Treatment Market Size, By Mode of Treatment, 2018-2023 (USD Billion)
Table 25 Europe Infectious Disease Treatment Market Size, By Mode of Treatment, 2025-2030 (USD Billion)
Table 26 Europe Infectious Disease Treatment Market Size, By Target Organism, 2018-2023 (USD Billion)
Table 27 Europe Infectious Disease Treatment Market Size, By Target Organism, 2025-2030 (USD Billion)
Table 28 Europe Infectious Disease Treatment Market Size, By Disease Type, 2018-2023 (USD Billion)
Table 29 Europe Infectious Disease Treatment Market Size, By Disease Type, 2025-2030 (USD Billion)
Table 30 Europe Infectious Disease Treatment Market Size, By End User, 2018-2023 (USD Billion)
Table 31 Europe Infectious Disease Treatment Market Size, By End User, 2025-2030 (USD Billion)
Table 32 Europe Infectious Disease Treatment Market Size, by Region, 2018-2023 (USD Billion)
Table 33 Europe Infectious Disease Treatment Market Size, by Region, 2025-2030 (USD Billion)
Table 34 Asia-Pacific Infectious Disease Treatment Market Size, By Mode of Treatment, 2018-2023 (USD Billion)
Table 35 Asia-Pacific Infectious Disease Treatment Market Size, By Mode of Treatment, 2025-2030 (USD Billion)
Table 36 Asia-Pacific Infectious Disease Treatment Market Size, By Target Organism, 2018-2023 (USD Billion)
Table 37 Asia-Pacific Infectious Disease Treatment Market Size, By Target Organism, 2025-2030 (USD Billion)
Table 38 Asia-Pacific Infectious Disease Treatment Market Size, By Disease Type, 2018-2023 (USD Billion)
Table 39 Asia-Pacific Infectious Disease Treatment Market Size, By Disease Type, 2025-2030 (USD Billion)
Table 40 Asia-Pacific Infectious Disease Treatment Market Size, By End User, 2018-2023 (USD Billion)
Table 41 Asia-Pacific Infectious Disease Treatment Market Size, By End User, 2025-2030 (USD Billion)
Table 42 Asia-Pacific Infectious Disease Treatment Market Size, by Region, 2018-2023 (USD Billion)
Table 43 Asia-Pacific Infectious Disease Treatment Market Size, by Region, 2025-2030 (USD Billion)
Table 44 RoW Infectious Disease Treatment Market Size, By Mode of Treatment, 2018-2023 (USD Billion)
Table 45 RoW Infectious Disease Treatment Market Size, By Mode of Treatment, 2025-2030 (USD Billion)
Table 46 RoW Infectious Disease Treatment Market Size, By Target Organism, 2018-2023 (USD Billion)
Table 47 RoW Infectious Disease Treatment Market Size, By Target Organism, 2025-2030 (USD Billion)
Table 48 RoW Infectious Disease Treatment Market Size, By Disease Type, 2018-2023 (USD Billion)
Table 49 RoW Infectious Disease Treatment Market Size, By Disease Type, 2025-2030 (USD Billion)
Table 50 RoW Infectious Disease Treatment Market Size, By End User, 2018-2023 (USD Billion)
Table 51 RoW Infectious Disease Treatment Market Size, By End User, 2025-2030 (USD Billion)
Table 52 RoW Infectious Disease Treatment Market Size, by Region, 2018-2023 (USD Billion)
Table 53 RoW Infectious Disease Treatment Market Size, by Region, 2025-2030 (USD Billion)
Table 54 Snapshot – Merck & Co., Inc. 
Table 55 Snapshot – Pfizer Inc.
Table 56 Snapshot – F. Hoffmann-La Roche Ltd
Table 57 Snapshot – GSK plc
Table 58 Snapshot – AstraZeneca
Table 59 Snapshot – Novartis AG
Table 60 Snapshot – Mylan N.V.
Table 61 Snapshot – Sanofi
Table 62 Snapshot – Gilead Sciences, Inc.
Table 63 Snapshot – Bayer AG

List of Figures

Figure 1 Market Coverage
Figure 2 Research Phases
Figure 3 Secondary Sources for Different Parameters
Figure 4 Methodology
Figure 5 Data Mining & Exploration
Figure 6 Data Triangulation
Figure 7 Assumptions for Market Estimation and Forecast
Figure 8 Market Synopsis
Figure 9 Global Infectious Disease Treatment Market - Growth Drivers and Restraints
Figure 10 Competitive Benchmark
Figure 11 Global Infectious Disease Treatment Market Highlight
Figure 12 Global Infectious Disease Treatment Market Size, By Mode of Treatment, 2018 - 2030 (USD Billion)
Figure 13 Global Infectious Disease Treatment Market Size, By Target Organism, 2018 - 2030 (USD Billion)
Figure 14 Global Infectious Disease Treatment Market Size, By Disease Type, 2018 - 2030 (USD Billion)
Figure 15 Global Infectious Disease Treatment Market Size, By End User, 2018 - 2030 (USD Billion)
Figure 16 Global Infectious Disease Treatment Market Size, by Region, 2018 - 2030 (USD Billion)
Figure 17 North America Infectious Disease Treatment Market Highlight
Figure 18 North America Infectious Disease Treatment Market Size, By Mode of Treatment, 2018 - 2030 (USD Billion)
Figure 19 North America Infectious Disease Treatment Market Size, By Target Organism, 2018 - 2030 (USD Billion)
Figure 20 North America Infectious Disease Treatment Market Size, By Disease Type, 2018 - 2030 (USD Billion)
Figure 21 North America Infectious Disease Treatment Market Size, By End User, 2018 - 2030 (USD Billion)
Figure 22 North America Infectious Disease Treatment Market Size, by Region, 2018 - 2030 (USD Billion)
Figure 23 Europe Infectious Disease Treatment Market Highlight
Figure 24 Europe Infectious Disease Treatment Market Size, By Mode of Treatment, 2018 - 2030 (USD Billion)
Figure 25 Europe Infectious Disease Treatment Market Size, By Target Organism, 2018 - 2030 (USD Billion)
Figure 26 Europe Infectious Disease Treatment Market Size, By Disease Type, 2018 - 2030 (USD Billion)
Figure 27 Europe Infectious Disease Treatment Market Size, By End User, 2018 - 2030 (USD Billion)
Figure 28 Europe Infectious Disease Treatment Market Size, by Region, 2018 - 2030 (USD Billion)
Figure 29 Asia-Pacific Infectious Disease Treatment Market Highlight
Figure 30 Asia-Pacific Infectious Disease Treatment Market Size, By Mode of Treatment, 2018 - 2030 (USD Billion)
Figure 31 Asia-Pacific Infectious Disease Treatment Market Size, By Target Organism, 2018 - 2030 (USD Billion)
Figure 32 Asia-Pacific Infectious Disease Treatment Market Size, By Disease Type, 2018 - 2030 (USD Billion)
Figure 33 Asia-Pacific Infectious Disease Treatment Market Size, By End User, 2018 - 2030 (USD Billion)
Figure 34 Asia-Pacific Infectious Disease Treatment Market Size, by Region, 2018 - 2030 (USD Billion)
Figure 35 RoW Infectious Disease Treatment Market Highlight
Figure 36 RoW Infectious Disease Treatment Market Size, By Mode of Treatment, 2018 - 2030 (USD Billion)
Figure 37 RoW Infectious Disease Treatment Market Size, By Target Organism, 2018 - 2030 (USD Billion)
Figure 38 RoW Infectious Disease Treatment Market Size, By Disease Type, 2018 - 2030 (USD Billion)
Figure 39 RoW Infectious Disease Treatment Market Size, By End User, 2018 - 2030 (USD Billion)
Figure 40 RoW Infectious Disease Treatment Market Size, by Region, 2018 - 2030 (USD Billion)